Internal Medicine, Hematology & Oncology · New York, NY
NPI
1881850626
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1275 York Ave
New York, NY, 10065
Phone (212) 639-4839
Groups this clinician bills Medicare through
Medicare paid, 2024
$77K
799 services
Medicare patients, 2024
266
Average age 75
Drug cost, 2024
$2.8M
546 prescriptions
Company payments, 2025
$10K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alison Moskowitz was code 99214 (office e&m - established), 430 times for 194 patients. In total Alison Moskowitz billed 799 services in 13 codes, and Medicare paid $77K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 430 | 194 | $84.11 | $36K |
| 99233 Hospital E&M - Subsequent | Facility | 132 | 38 | $104.32 | $14K |
| 99215 Office E&M - Established | Office | 122 | 64 | $133.90 | $16K |
| 99238 Hospital Discharge Management | Facility | 29 | 27 | $71.64 | $2,078 |
| 99223 Hospital E&M - Initial | Facility | 17 | 14 | $152.31 | $2,589 |
| 99205 Office E&M - New | Office | 16 | 16 | $167.53 | $2,681 |
| 99213 Office E&M - Established | Office | 15 | 13 | $59.51 | $893 |
By year: 2022 $68K for 682 services; 2023 $69K for 694 services; 2024 $77K for 799 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alison Moskowitz prescribed most often to Medicare patients was Acyclovir, with 48 prescriptions and refills. In total Alison Moskowitz wrote 546 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 48 | 64 | 14 | $579 |
| Levothyroxine Sodium Generic | 45 | 61 | 11 | $521 |
| Prednisone Generic | 38 | 38 | 18 | $104 |
| Gabapentin Generic | 33 | 45 | Under 11 | $362 |
| Copiktra Duvelisib | 32 | 32 | Under 11 | $1.4M |
| Bexarotene Generic | 24 | 24 | Under 11 | $310K |
| Pantoprazole Sodium Generic | 22 | 33 | 11 | $291 |
| Calquence Acalabrutinib Maleate | 21 | 21 | Under 11 | $263K |
| Fenofibrate Fenofibrate Nanocrystallized | 20 | 34 | Under 11 | $254 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 13 | 24 | Under 11 | $45.24 |
| Jakafi Ruxolitinib Phosphate | 11 | 11 | Under 11 | $180K |
| Pegasys Peginterferon Alfa-2a | 11 | 11 | Under 11 | $48K |
| Entecavir Generic | 11 | 15 | Under 11 | $2,060 |
| Imbruvica Ibrutinib | 11 | 11 | Under 11 | $211K |
Brand drugs: 142 claims; generic drugs: 404 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alison Moskowitz $10K ($9,221 in general payments such as food, travel and fees and $1,270 for research) from 6 companies. The largest payer was Merck Sharp & Dohme LLC with $8,960.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.